Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Cytidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.62 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.62 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.62 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.56 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.56 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.54 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | TK1 | P04183 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxribtimine SCHEMBL6518312 | 0.90 | LMNA (0.62) | LMNASMN1; SMN2THRBMTORMDM2 | |
| Doxribtimine SCHEMBL787714 | 0.90 | LMNA (0.62) | LMNASMN1; SMN2THRBMTORMDM2 | |
| Cytarabine SCHEMBL8980109 | 0.89 | LMNA (0.51) | LMNASMN1; SMN2THRBMTORMDM2 | |
| Cytidine SCHEMBL574822 | 0.87 | LMNA (0.67) | LMNATHRBMTORMDM2NCOA1 | |
| 5-Fluorouridine SCHEMBL4390966 | 0.87 | LMNA (0.83) | LMNASMN1; SMN2P2RY6ALOX12ADRA1A | |
| 5-Fluorouridine SCHEMBL4390962 | 0.87 | LMNA (0.83) | LMNASMN1; SMN2P2RY6ALOX12ADRA1A | |
| Cytidine SCHEMBL7196447 | 0.87 | LMNA (0.79) | LMNASMN1; SMN2THRBMTORMDM2 | |
| Doxribtimine SCHEMBL29124320 | 0.86 | P2RY2 (0.60) | LMNASMN1; SMN2THRBMTORMDM2 | |
| Floxuridine SCHEMBL15375760 | 0.86 | LMNA (0.72) | LMNASMN1; SMN2PLA2G1BATG4BP2RY2 | |
| Uridine SCHEMBL18249683 | 0.85 | P2RY2 (0.71) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585855-B2 | Bengamides with a substituted caprolactam cycle, method for the preparation thereof, compositions containing them and use thereof | AVENTIS PHARMA SA (FR) | 2009-09-08 | — | — | US | disclosed |
| US-20080318928-A1 | BENGAMIDES WITH A SUBSTITUTED CAPROLACTAM CYCLE, METHOD FOR THE PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318928-A1 | BENGAMIDES WITH A SUBSTITUTED CAPROLACTAM CYCLE, METHOD FOR THE PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | CDK4, CCNI, CCNT2 | LMNA 274/4885SMN1; SMN2 3147/4885THRB 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.